197 related articles for article (PubMed ID: 2363126)
1. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
[TBL] [Abstract][Full Text] [Related]
2. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cyclic AMP and phorbol ester on PAI-2 synthesis in a leukemic cell line PL-21 and on u-PA secretion in a pre-B cell lymphoma cell line RC-K8].
Niiya K; Sakuragawa N
Nihon Rinsho; 1992 Feb; 50(2):325-9. PubMed ID: 1319513
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone and phorbol ester, but not cytokines, increase the production of plasminogen activator inhibitor type-2 in the PL-21 human promyelocytic leukemia cell line.
Niiya K; Takeuchi T; Kobayashi M; Miyoshi I; Hayashi T; Sakuragawa N
Thromb Haemost; 1991 Aug; 66(2):232-8. PubMed ID: 1771617
[TBL] [Abstract][Full Text] [Related]
7. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
8. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells.
Schleef RR; Wagner NV; Loskutoff DJ
J Cell Physiol; 1988 Feb; 134(2):269-74. PubMed ID: 3257967
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies.
Rondeau E; Mougenot B; Lacave R; Peraldi MN; Kruithof EK; Sraer JD
Clin Nephrol; 1990 Feb; 33(2):55-60. PubMed ID: 2107050
[TBL] [Abstract][Full Text] [Related]
10. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681
[TBL] [Abstract][Full Text] [Related]
11. [Plasminogen activators and plasminogen activator inhibitor type-1 in human endometrium].
Chen GA; Feng Q; Zhang LZ; Liu YX
Sheng Li Xue Bao; 1992 Oct; 44(5):502-9. PubMed ID: 1293766
[TBL] [Abstract][Full Text] [Related]
12. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators and their inhibitors in the neuromuscular system: I. Developmental regulation of plasminogen activator isoforms during in vitro myogenesis in two cell lines.
Festoff BW; Rao JS; Maben C; Hantaï D
J Cell Physiol; 1990 Aug; 144(2):262-71. PubMed ID: 2199466
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
15. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
16. Isolation of multiple types of plasminogen activator inhibitors from vascular smooth muscle cells.
Laug WE; Aebersold R; Jong A; Rideout W; Bergman BL; Baker J
Thromb Haemost; 1989 Jun; 61(3):517-21. PubMed ID: 2799763
[TBL] [Abstract][Full Text] [Related]
17. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells.
Laug WE
Thromb Haemost; 1985 Apr; 53(2):165-9. PubMed ID: 3927503
[TBL] [Abstract][Full Text] [Related]
18. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
19. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Dong Q; Zhou MH; Subbarao V; Ts'ao CH
Br J Exp Pathol; 1988 Oct; 69(5):685-95. PubMed ID: 3143395
[TBL] [Abstract][Full Text] [Related]
20. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
